Cue Biopharma Inc. Announces Annual Stockholders Meeting

Reuters03-17
<a href="https://laohu8.com/S/CUE">Cue Biopharma</a> Inc. Announces Annual Stockholders Meeting

Cue Biopharma will hold its 2026 annual meeting online on April 13, 2026 at https://www.virtualshareholdermeeting.com/CUE2026. Shareholders will vote on the election of seven director nominees: Usman Azam, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, Jill Broadfoot and Pasha Sarraf. The meeting agenda also includes ratification of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and an advisory vote on executive compensation. Shareholders will also consider a certificate amendment to authorize a reverse stock split with a ratio between 1-for-30 and 1-for-50.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108301), on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment